SURMOUNT-5 trial results

Adults without diabetes who had obesity or overweight with a weight-related condition.

MounjaroWegovy injection

Open-label, randomised head-to-head trial using each participant’s maximum tolerated dose. Modified treatment-regimen analysis.

Mean body weight change at 72 weeks

Mean body weight change at 72 weeks
Trial arm	Result
Tirzepatide 10 or 15 mg	−20.2%
Semaglutide 1.7 or 2.4 mg	−13.7%

Safety. Gastrointestinal events were most common in both groups, mainly during dose escalation.